Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 209-143-5 | CAS number: 556-88-7
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Skin sensitisation
Administrative data
- Endpoint:
- skin sensitisation: in vivo (non-LLNA)
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 22 Aug - 12 Oct 1984
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 988
- Report date:
- 1988
Materials and methods
Test guidelineopen allclose all
- Qualifier:
- according to guideline
- Guideline:
- other: EPA 560/6-82-001
- Deviations:
- yes
- Remarks:
- see section "Any other information on material and methods"
- Qualifier:
- according to guideline
- Guideline:
- other: Buehler dermal sensitization test. LAIR Standard Operating Procedure OP-STX-82, Letterman Army Institute of Research, Presidio of San Francisco, CA. 18 May 1984
- GLP compliance:
- yes
- Type of study:
- Buehler test
- Justification for non-LLNA method:
- Study from 1988 is readily available.
Test material
- Reference substance name:
- 1-nitroguanidine
- EC Number:
- 209-143-5
- EC Name:
- 1-nitroguanidine
- Cas Number:
- 556-88-7
- Molecular formula:
- CH4N4O2
- IUPAC Name:
- N-nitroguanidine
- Reference substance name:
- Sodium sulphate
- EC Number:
- 231-820-9
- EC Name:
- Sodium sulphate
- Cas Number:
- 7757-82-6
- Molecular formula:
- Na2O4S
- IUPAC Name:
- disodium sulfate
- Reference substance name:
- Sodium nitrate
- EC Number:
- 231-554-3
- EC Name:
- Sodium nitrate
- Cas Number:
- 7631-99-4
- Molecular formula:
- HNO3.Na
- IUPAC Name:
- sodium nitrate
- Reference substance name:
- 4,6-diamino-1,3,5-triazin-2(1H)-one
- EC Number:
- 211-455-1
- EC Name:
- 4,6-diamino-1,3,5-triazin-2(1H)-one
- Cas Number:
- 645-92-1
- Molecular formula:
- C3H5N5O
- IUPAC Name:
- 4,6-diamino-1,3,5-triazin-2(1H)-one
- Reference substance name:
- 6-amino-1,3,5-triazine-2,4(1H,3H)-dione
- EC Number:
- 211-456-7
- EC Name:
- 6-amino-1,3,5-triazine-2,4(1H,3H)-dione
- Cas Number:
- 645-93-2
- Molecular formula:
- C3H4N4O2
- IUPAC Name:
- 6-amino-1,3,5-triazine-2,4(1H,3H)-dione
- Test material form:
- solid: particulate/powder
Constituent 1
impurity 1
impurity 2
impurity 3
impurity 4
- Specific details on test material used for the study:
- Test substance supplier Sunflower AAP
In vivo test system
Test animals
- Species:
- guinea pig
- Strain:
- Hartley
- Sex:
- male
- Details on test animals and environmental conditions:
- TEST ANIMALS
- Source: Simonsen Laboratories, Gilroy, CA
- Age at study initiation: approx. 4 weeks
- Weight at receipt: 140-233 g
- Housing: individual housing in stainless steel wire mesh cages in racks equipped with automatically flushing dump tanks; no bedding was used in any of the cages
- Diet (e.g. ad libitum): Certified Pig Chow Diet 5026 (Ralstom Purina Company, Checkerboard Square, St. Louis, MD 63188)
- Water: continous drip from a central line
- Acclimation period: approx. 3 weeks
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 22.2 -25.6
- Humidity (%): 28-50 (occasional spikes as high as 70% > room washing)
- Air changes (per hr):
- Photoperiod (hrs dark/hrs light): 12/12
Study design: in vivo (non-LLNA)
Inductionopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- physiological saline
- Concentration / amount:
- NiGu was applied as a 10 % solution. A pilot study, using 100 %, 10 %, 1 %, and 0.1 % concentrations, indicated 10 % solution to be the highest non-irritating concentration under the conditions of this test.
Challengeopen allclose all
- Route:
- epicutaneous, occlusive
- Vehicle:
- physiological saline
- Concentration / amount:
- NiGu was applied as a 10 % solution. A pilot study, using 100 %, 10 %, 1 %, and 0.1 % concentrations, indicated 10 % solution to be the highest non-irritating concentration under the conditions of this test.
- No. of animals per dose:
- Ten animals were assigned to each of four groups by a stratified randomization technique based on their body weights.
- Details on study design:
- RANGE FINDING TESTS:
A pilot study, using 100 %, 10 %, 1 %, and 0.1 % concentrations, indicated the 10 % solution to be the highest non-irritating concentration under the conditions of this test.
MAIN STUDY
A. INDUCTION EXPOSURE
- Site: no details reported; the same application site was used for each induction dose; to distinguish between reactions from repeated insult and sensitization, duplicate patches of the challenge dose were applied, one on the old site and one on a new site
- Negative control group: to distinguish between reactions from primary irritation and sensitization, negative control groups were added which received only the challenge dose (nitroguanidine)
- Positive control group: dinitrochlorobenzene (DNCB), a known potent sensitizing agent, was applied to one group, at a 0.1 % concentration
- Vehicle control group: isotonic saline was applied to one group
- Frequency of applications: once a week for three weeks
- Duration: 6 hours under a closed patch
- Experimental, saline control, and positive control groups: dosed with 0.5 ml of the appropriate compound applied topically under a one-inch square guze patch; this procedure was performed for three consecutive weeks (12 Sep, 19 Sep, and 26 Sep 1984); the day before each dosing a three-inch square area on the left side of the animal was clipped with an electric clipper and then shaved with an electric razor
- The patch was taped with with hypoallergenic surgical tape to the same site each time and the animal was wrapped several times with Vetrap
- The patch was left in place for six hours
- When the wrap and patch were removed, the area under the patch was merked off for scoring
- Evaluation (h after each induction dose): skin was scored 24 and 48 h after induction
B. CHALLENGE EXPOSURE
- Animals were challenged 2 weeks following the third induction phase
- Test groups: the experimental group and the positive control group received two 0.5 ml doses, one applied to the old site on the left side and the other to a new site on the right side
- Control group: negative and vehicle control groups only received a single 0.5 ml dose which was applied to the left side
- Exposure period: 6 hours under a closed patch
- Evaluation (h after challenge): skin was scored 24 and 48 h after challenge
OTHER:
A. Compound preparation:
- mixing of 0.5 g NGu with 0.5 ml of isotonic saline to make a paste
- dinitrochlorobenzene dosing solution was prepared by first adding 30 mg DNCB to 1 ml of propylene glycol and this heating until dissolved (approx. 40 °C); to this 29 ml of 0.9% sodium chloride solution were added, to give a final concentration of 0.1 % (w/v); this solution was heated to 65 °C and vortexed before application to keep the DNCB in solution; DNCB solutions were prepared fresh for each application day - Positive control substance(s):
- yes
- Remarks:
- Dinitrochlorobenzene
Results and discussion
- Positive control results:
- DNCB produced a positive response at all time points. Between 40 % and 100 % of the DNCB-treated animals exhibited a response 24 h following the second and/or thirs induction and challenge doses. These reactions persisted, yielding scorable effects in 20 to 90% of the animals at 48 h after dosing.
Severity scores for these responses to DNCB ranged from 0.2 to 1.0 at the 24-hour scoring period; see table 3). The highest score, 1.0, was observed on the left (induction) side in response to the challenge dose. By 48 h the reactions had subsided somewhat; consequently, the severity range decreased to 0.1 to 0.95 (Table 4).
In vivo (non-LLNA)
Resultsopen allclose all
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- test chemical
- Dose level:
- 10 % concentration solution
- No. with + reactions:
- 0
- Total no. in group:
- 9
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: test group. Dose level: 10 % concentration solution. No with. + reactions: 0.0. Total no. in groups: 9.0. Clinical observations: not observed.
- Key result
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- test chemical
- Dose level:
- 10 % concentration solution
- No. with + reactions:
- 0
- Total no. in group:
- 9
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: test group. Dose level: 10 % concentration solution. No with. + reactions: 0.0. Total no. in groups: 9.0. Clinical observations: not observed.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- positive control
- Dose level:
- 0.1 % (w/v)
- No. with + reactions:
- 9
- Total no. in group:
- 10
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: positive control. Dose level: 0.1 % (w/v). No with. + reactions: 9.0. Total no. in groups: 10.0. Clinical observations: not observed.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- positive control
- Dose level:
- 0.1 % (w/v)
- No. with + reactions:
- 9
- Total no. in group:
- 10
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: positive control. Dose level: 0.1 % (w/v). No with. + reactions: 9.0. Total no. in groups: 10.0. Clinical observations: not observed.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- No. with + reactions:
- 1
- Total no. in group:
- 10
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. No with. + reactions: 1.0. Total no. in groups: 10.0. Clinical observations: not observed.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- No. with + reactions:
- 0
- Total no. in group:
- 10
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. No with. + reactions: 0.0. Total no. in groups: 10.0. Clinical observations: not observed.
- Reading:
- 1st reading
- Hours after challenge:
- 24
- Group:
- negative control
- Dose level:
- 10 % concentration solution
- No. with + reactions:
- 0
- Total no. in group:
- 9
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 1st reading. . Hours after challenge: 24.0. Group: negative control. Dose level: 10 % concentration solution. No with. + reactions: 0.0. Total no. in groups: 9.0. Clinical observations: not observed.
- Reading:
- 2nd reading
- Hours after challenge:
- 48
- Group:
- negative control
- Dose level:
- 10 % concentration solution
- No. with + reactions:
- 0
- Total no. in group:
- 9
- Clinical observations:
- not observed
- Remarks on result:
- other: Reading: 2nd reading. . Hours after challenge: 48.0. Group: negative control. Dose level: 10 % concentration solution. No with. + reactions: 0.0. Total no. in groups: 9.0. Clinical observations: not observed.
Any other information on results incl. tables
Skin reactions were assigned scores according to Buehler’s grading system: 0 (no reaction), 1 (slight erythema), 2 (moderate erythema) and 3 (marked erythema). The results are expressed both in terms of incidence (the number of animals showing responses of 1 or greater at either 14 or 48 h) and severity (the sum of the test scores divided by the number of animals tested). Results from the left side are compared with the right side and with the negative control group.
Tables 1 and 2 summarize the incidence of reactions 24 and 48 h after each dose. There were no reactions observed in response to nitroguanidine administration, either at 24 or 48 h.
Table 1: Incidences of skin reactions after 24 h
|
Induction |
Challenge |
|||
Test Group |
First |
Second |
Third |
Left |
Right |
Nitroguanidine |
0/10 |
0/9 |
0/9 |
0/9 |
0/9 |
Negative Control * |
---- |
---- |
---- |
0/9 |
0/9 |
Saline Vehicle |
1/10 |
0/10 |
0/10 |
1/10 |
0/10 |
DNCB |
1/10 |
4/10 |
4/10 |
9/10 |
8/10 |
* The Negative Control Group received only a challenge dose of the test compound.
Table 2: Incidences of skin reactions after 48 h
|
Induction |
Challenge |
|||
Test Group |
First |
Second |
Third |
Left |
Right |
Nitroguanidine |
0/10 |
0/9 |
0/9 |
0/9 |
0/9 |
Negative Control * |
---- |
---- |
---- |
0/9 |
0/9 |
Saline Vehicle |
0/10 |
0/10 |
0/10 |
0/10 |
0/10 |
DNCB |
1/10 |
2/10 |
6/10 |
9/10 |
6/10 |
* The Negative Control Group received only a challenge dose of the test compound.
This lack of response is reflected in Tables 3 and 4, which report the severity of skin reactions at 24 and 48 hours. Response severity for each group is calculated by summing the scores of responding animals and dividing by the total number of animals within the group. This produced a severity index of 0.0 for nitroguanidine.
Table 3: Severity of skin reactions after 24 h
|
Induction |
Challenge |
|||
Test Group |
First |
Second |
Third |
Left |
Right |
Nitroguanidine |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Negative Control * |
---- |
---- |
---- |
0.0 |
0.0 |
Saline Vehicle |
0.1 |
0.0 |
0.0 |
0.05 |
0.0 |
DNCB |
0.05 |
0.3 |
0.2 |
1.0 |
0.95 |
* The Negative Control Group received only a challenge dose of the test compound.
Table 4: Severity of skin reactions after 48 h
|
Induction |
Challenge |
|||
Test Group |
First |
Second |
Third |
Left |
Right |
Nitroguanidine |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
Negative Control * |
---- |
---- |
---- |
0.0 |
0.0 |
Saline Vehicle |
0.0 |
0.0 |
0.0 |
0.0 |
0.0 |
DNCB |
0.05 |
0.3 |
0.4 |
0.95 |
0.75 |
* The Negative Control Group received only a challenge dose of the test compound.
Applicant's summary and conclusion
- Interpretation of results:
- GHS criteria not met
- Conclusions:
- Nitroguanidine exhibited no potential for inducing dermal sensitization based on a zero percent sensitization rate in this study.
- Executive summary:
In a dermal sensitization study with Nitroguanidine in saline solution, nine four weeks old, male guinea pigs (Hartley strain) were tested in accordance with LAIR SOP-OP-STX-82 “Buehler Dermal Sensitization Test” and EPA Guideline 560/6-82-001.
Nitroguanidine was evaluated for its ability to elicit a delayed hypersensitivity reaction via dermal contact. Using the method of Buehler and Griffith, no response indicative of dermal sensitization produced by nitroguanidine could be observed. Therefore, in this study, nitroguanidine showed no evidence of potential to elicit an allergic response.
Any sensitizing produced by nitroguanidine would have been easily detected by this study. An allergic response was reliably elicited by DNCB in the present group of animals. This response to DNCB was characteristic of that observed previously within the institute. Although DNCB is capable of producing primary irritation, the responses observed in this study were indicative of an allergic reaction since the concentration of DNCB used for the induction and challenge doses was too low to produce primary irritation. With the exception of a very slight irritation response in one animal 24 hours after the first induction, responses to DNCB were observed only after two or more exposures and the severity generally increased with the number of previous exposures.
Nitorguanidine, based on a zero percent sensitization rate in this study, exhibited no potential for inducing dermal sensitization.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.